Clinical Trial Update: Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the efficacy and safety of twice-daily 60 mg AZD9668 in chronic obstructive pulmonary disease patients on background budesonide/formot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD9668 (AZD9668)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED | Results posted: 2012-08-03